What Not to Take With Retatrutide: Interactions, Foods & Safety Retatrutide is an investigational triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently in clinical trials for obesity and type 2 diabetes
5 More serious GI adverse events have been reported with GLP-1 RAs too, which increase the risk of pancreatitis, bowel obstruction, and gastroparesis
& Pachitariu, M
47,48 Human studies yield somewhat mixed results regarding the impact of GIP on bone metabolism
The most frequently reported side effects of Wegovy were nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, abdominal distension, belching, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease
She experienced sleep disruption, mood changes, and weight gain, in addition to some challenges with digestion